| Date | Title | Description |
| 13.08.2026 | Tenosynovial Giant Cell Tumor Treatment Market to Witness Robust Growth Driven by Precision Medicine and Targeted Oncology Innovation | Overview
According to DataM Intelligence, the global tenosynovial giant cell tumor treatment market size reached USD 8.88 billion in 2025 and is forecast to reach USD 13.40 billion by 2035, expanding at a CAGR of 4.2% during the 2026–2035 f... |
| 02.07.2026 | Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSC... | SHANGHAI, July 2, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/N... |
| 24.06.2026 | Abbisko Therapeutics Deepens R&D Collaboration with Lilly | SHANGHAI, June 24, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with ... |
| 01.04.2026 | Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma | SHANGHAI, April 1, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inh... |
| 31.03.2026 | Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children | SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleared the Investigationa... |
| 13.01.2026 | Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor | SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, oral... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong.
In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 18.06.2025 | A New Dawn in Oncology and ADHD Treatment: Abbisko and ArkBio Lead the Charge | In the ever-evolving landscape of medicine, two companies are making headlines: Abbisko Therapeutics and ArkBio. Both are pushing boundaries, seeking to redefine treatment paradigms in oncology and ADHD. Their recent advancements signal hop... |
| 16.06.2025 | Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC | SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4... |
| 10.06.2025 | Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT | SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective... |
| 26.05.2025 | Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC | SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designa... |
| 17.05.2025 | The Dawn of Precision Medicine: Nordic Bioscience and Abbisko Therapeutics Lead the Charge | In the ever-evolving landscape of healthcare, precision medicine stands as a beacon of hope. It promises tailored treatments that align with individual patient profiles. Two companies, Nordic Bioscience and Abbisko Therapeutics, are at the ... |
| 13.05.2025 | Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr... | SHANGHAI, May 13, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocell... |
| 28.04.2025 | 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 | SHANGHAI, April 28, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illi... |
| 09.12.2024 | 2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting | SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD)... |
| 19.09.2024 | Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC | SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety... |
| 28.06.2024 | 50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress | SHANGHAI, June 28, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atez... |
| 26.05.2024 | Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck | - |
| 09.01.2024 | Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021） | SHANGHAI, Jan. 9, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（O... |
| 04.12.2023 | Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck | SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms o... |
| 02.03.2023 | Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376 | SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shan... |
| 30.01.2023 | Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021） | SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA... |
| 18.01.2023 | Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD | SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been approved by the National Medical Products Adminis... |
| 04.07.2022 | Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 | SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial... |
| 14.12.2021 | Carlyle : Raises Nearly $8 Billion for Ninth U.S. Real Estate Fund | Washington, DC - Global investment firm Carlyle (NASDAQ: CG) today announced that it has raised approximately $8 billion for its ninth U.S. real estate opportunity fund, Carlyle Realty Partners IX (CRP IX), exceeding its $6 billion initial ... |
| 09.01.2021 | Reuters: Chinese biotech firm Abbisko raises $123 million in Ser D | - |
| 08.01.2021 | Carlyle : Chinese biotech firm Abbisko raises $123 million from Carlyle, Warburg | Abbisko said in a news release that Carlyle led the latest fundraising with Warburg, OrbiMed, Lake Bleu Capital, and an unnamed Boston-based investor as the joint leading investors.
Other investors include Janchor Partners, Sage Partners, S... |
| 08.01.2021 | Carlyle leads $123m round in Shanghai-based biopharma firm Abbisko | Abbisko Therapeutics, a Shanghai-based biopharmaceutical firm, announced on Friday the completion of a Series D funding round at $123 million to advance the startup’s clinical programmes and to expand its portfolio in the discovery and prec... |
| 08.01.2021 | Abbisko Therapeutics Co. Ltd. announced that it has received $123 million in funding from a group of investors | Abbisko Therapeutics Co. Ltd. announced that it has received $123 million in a round of funding co-led by new investors The Carlyle Group Inc. (NasdaqGS:CG), Warburg Pincus LLC, OrbiMed Advisors LLC, Lake Bleu Capital (Hong Kong) Limited, a... |
| 08.01.2021 | Carlyle : Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by the Carlyle Group | Shanghai - Abbisko Therapeutics Co., Ltd. announced the recent completion of its Series D financing of $123 million.
This investment was led by The Carlyle Group, with
Warburg Pincus, OrbiMed, Lake Bleu Capital, and a Boston-based investor ... |
| 08.01.2021 | Carlyle leads $123m round in Shanghai-based biopharma firm Abbisko | Premium
Abbisko Therapeutics, a Shanghai-based biopharmaceutical firm, announced on Friday the completion of a Series D funding round at $123 million to advance the startup’s clinical programmes and to expand its portfolio in the discovery ... |
| 08.01.2021 | THE CARLYLE GROUP INC.
Carlyle : Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by the Carlyle Group | Shanghai - Abbisko Therapeutics Co., Ltd. announced the recent completion of its Series D financing of $123 million.
This investment was led by The Carlyle Group, with
Warburg Pincus, OrbiMed, Lake Bleu Capital, and a Boston-based investor ... |
| 08.01.2021 | THE CARLYLE GROUP INC.
Carlyle : Chinese biotech firm Abbisko raises $123 million from Carlyle, Warburg | Abbisko said in a news release that Carlyle led the latest fundraising with Warburg, OrbiMed, Lake Bleu Capital, and an unnamed Boston-based investor as the joint leading investors.
Other investors include Janchor Partners, Sage Partners, S... |
| 17.12.2020 | THE CARLYLE GROUP INC.
Carlyle : AlpInvest Partners completes fundraising for seventh secondaries program reaching hard cap of $9 billion | Includes more than 170 New and Existing Investors New York, Amsterdam and Hong Kong- AlpInvest Partners, The Carlyle Group's dedicated private equity primary fund, co-investment, and secondary solutions platform, has raised $9 billion for A... |
| 17.12.2020 | Carlyle : AlpInvest Partners completes fundraising for seventh secondaries program reaching hard cap of $9 billion | Includes more than 170 New and Existing Investors New York, Amsterdam and Hong Kong- AlpInvest Partners, The Carlyle Group's dedicated private equity primary fund, co-investment, and secondary solutions platform, has raised $9 billion for A... |
| 25.03.2020 | Oprah day in biotech: Regenacy gets $30M, Abbisko gets $70M, Castle Creek gets $75M | → A young biotech in Waltham called Regenacy announced a $30 million Series A, led by Cobro Ventures and Taiwania Capital Management. The company was a spinout from the biotech Acetylon after it sold itself to Celgene i... |
| 25.03.2020 | Chinese biopharma firm Abbisko closes $70m Series C round led by Temasek | Premium
Shanghai-based Abbisko Therapeutics has secured $70 million in a Series C round of financing led by Singaporean state-owned investment firm Temasek, bringing the total capital raised by the Chinese biopharma firm to $140 million.
Co... |
| 25.03.2019 | China’s Qiming Ventures leads $42m funding for Abbisko Therapeutics | Premium
Shanghai-based Abbisko Therapeutics has closed a $42-million Series B funding round led by venture capital firm Qiming Venture Partners.
Continue reading this story with a subscription to DealStreetAsia.
Subscribe
Already a subscrib... |
| 08.02.2017 | Chinese I-O biotech Abbisko raises $28M in first-round funding | Shanghai-based startup Abbisko Therapeutics has raised $28 million in a Series A financing that will be used to advance its cancer immunotherapies into clinical trials.
The investment round—by Lilly Asia Ventures, Sinopharm Capital, Jianxin... |
| - | China's Qiming leads $42m funding for Abbisko Therapeutics | - |
